Physician profile
David P Barnes
NPI 1215129721
$2,972.39
in general payments reported to CMS, 2019-2025
37 companies · $446 in 2025
The $446 reported for 2025 was more than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $567 · 2020: $87.24 · 2021: $528 · 2022: $436 · 2023: $401 · 2024: $507 · 2025: $446.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,306 · Education: $48.84.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,305.79 |
| Education | $48.84 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $739.76 | 2021-2025 | Ubrelvy, Vraylar, Qulipta |
| Pfizer INC. | $282.95 | 2019-2024 | |
| Lilly USA, LLC | $170.48 | 2022-2025 | Mounjaro, Zepbound |
| Novo Nordisk INC | $155.71 | 2019-2024 | Rybelsus, Ozempic |
| Astrazeneca Pharmaceuticals Lp | $151.10 | 2019-2025 | Airsupra, Breztri |
| Otsuka America Pharmaceutical, INC. | $132.18 | 2023-2025 | Rexulti |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $116.06 | 2024-2025 | Caplyta |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $109.24 | 2019-2025 | Xifaxan |
| Merck Sharp & Dohme LLC | $98.90 | 2019-2021 | |
| Takeda Pharmaceuticals U.S.A., INC. | $88.33 | 2019-2024 | Trintellix |
| Kowa Pharmaceuticals America, INC. | $80.33 | 2021-2025 | Zoryve |
| Amgen INC. | $64.46 | 2019-2021 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $61.72 | 2019-2021 | |
| Novartis Pharmaceuticals Corporation | $58.53 | 2022-2025 | |
| Allergan, INC. | $57.08 | 2019-2020 |
Show all 37 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Corium, LLC | $51.81 | 2023-2024 | Azstarys |
| Amarin Pharma, INC. | $49.58 | 2019-2021 | |
| Dexcom, INC. | $47.40 | 2021 | |
| Glaxosmithkline, LLC. | $45.43 | 2019-2024 | Arexvy, Trelegy Ellipta |
| Eisai INC. | $39.89 | 2021-2022 | |
| Biohaven Pharmaceuticals, INC. | $35.08 | 2021 | |
| Lundbeck LLC | $34.80 | 2025 | Rexulti |
| Sanofi-Aventis U.S. LLC | $31.98 | 2019-2023 | |
| Axsome Therapeutics, INC. | $31.14 | 2025 | Symbravo |
| Ucb, INC. | $27.27 | 2022 | |
| Astellas Pharma US INC | $26.43 | 2021-2024 | Veozah |
| Janssen Pharmaceuticals, INC | $23.63 | 2019 | |
| Vbi Vaccine (Delaware) INC. | $20.40 | 2022 | |
| Bayer Healthcare Pharmaceuticals INC. | $19.18 | 2023 | |
| Esperion Therapeutics, INC. | $18.25 | 2021 | |
| Scilex Pharmaceuticals INC. | $17.44 | 2019 | |
| Vertex Pharmaceuticals Incorporated | $17.35 | 2025 | |
| Daiichi Sankyo INC. | $15.35 | 2021 | |
| Acadia Pharmaceuticals INC | $14.58 | 2019 | |
| Abbott Laboratories | $14.39 | 2023 | Freestyle Libre 3 |
| Circassia INC. | $12.38 | 2019 | |
| Shire North American Group INC | $11.80 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw David Barnes listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.